Review: The Role of MOP and DOP Receptors in Treatment of Diarrheapredominant Irritable Bowel Syndrome

Author(s): Agata Jarmuż, Marta Zielińska, Karolina Leń, Martyna Banaszek, Martin Storr, Jakub Fichna

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 16 , Issue 18 , 2016

Become EABM
Become Reviewer
Call for Editor


Diarrhea-predominant irritable bowel syndrome (IBS-D) is a frequent functional disorder of the gastrointestinal (GI) tract affecting nearly one fifth of the worldwide population. IBS-D is associated with numerous symptoms including diarrhea, bloating, abdominal pain and discomfort, which significantly reduce patients’ quality of life. Due to a complex and unclear pathogenesis, effective therapy against IBS-D has not been developed yet. Nowadays, treatment is focused on non-pharmacological (e.g. changes in diet and life style) and pharmacological (e.g. loperamide, ramosetron, rifaximin) approaches. The endogenous opioid system is responsible for the maintenance of homeostasis in the GI tract. Activation of the intestinal opioid receptors (ORs), in particular μ (MOP) and δ (DOP) results in reduction of epithelial secretion and increase of water/electrolyte absorption; moreover, opioids are strong analgesic agents. Thus, ligands of ORs are a promising target in IBS-D treatment. In this review, we discuss the role of ORs in the pathogenesis of IBS-D and the use of “classical” and novel, such as P-317, eluxadoline and biphalin MOP and DOP receptor ligands in preclinical and clinical trials.

Keywords: Diarrhea, irritable bowel syndrome, MOP/DOP receptor ligands, opioid receptors, opioids.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 27 October, 2016
Page: [1462 - 1469]
Pages: 8
DOI: 10.2174/1389557516666160804165318
Price: $65

Article Metrics

PDF: 32
PRC: 2